Knockdown of ALDH1A3 reduces breast cancer stem cell marker CD44 via the miR‑7‑TGFBR2‑Smad3‑CD44 regulatory axis

Pan,Meng; Li,Miao; Guo,Mei; Zhou,Huiying; Xu,Hui; Zhao,Fengshu; Mei,Feng; Xue,Rui; Dou,Jun

doi:10.3892/etm.2021.10527

Knockdown of ALDH1A3 reduces breast cancer stem cell marker CD44 via the miR‑7‑TGFBR2‑Smad3‑CD44 regulatory axis

Authors:
- Meng Pan
- Miao Li
- Mei Guo
- Huiying Zhou
- Hui Xu
- Fengshu Zhao
- Feng Mei
- Rui Xue
- Jun Dou
View Affiliations

Affiliations: Department of Judicial Identification, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing, Jiangsu 210009, P.R. China
Published online on: August 2, 2021 https://doi.org/10.3892/etm.2021.10527
Article Number: 1093
Copyright: © Pan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inhibition of aldehyde dehydrogenase 1 family member A3 (ALDH1A3) has been revealed to lead to significant increase of microRNA (miR)‑7 expression and decrease of CD44 expression in breast cancer stem cells (BCSCs), however the mechanism is not clear. The aim of the present study was to investigate the regulatory relationship between ALDH1A3, miR‑7, and CD44 in BCSCs. The expression of ALDH1A3 was inhibited by small interfering RNA (siRNA or si), and the expression of miR‑7 was detected by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). Then, the ratio of CD44⁺ cells was analyzed by flow cytometry in MDA‑MB‑231 cells. The dual‑luciferase reporter system was used to demonstrate that miR‑7 binds to transforming growth factor‑β receptor 2 (TGFBR2) 3'UTR, and ChIP‑PCR determined whether the transcription factor Smad3 binds to the upstream regulatory region of the CD44 promoter. The results revealed that siALDH1A3 downregulated ALDH1A3 and promoted miR‑7 expression, which resulted in downregulation of CD44 expression. siALDH1A3 also downregulated the CD44 expression on the surface of MDA‑MB‑231 cells and inhibited the G2/M phase in BCSCs as analyzed by flow cytometry. In addition, lenti‑miR‑7 cells transfected with TGF‑β1 + SB431542 revealed that lenti‑miR‑7 inhibited the TGF‑β1 pathway by inhibiting Smad2/3/4 expression and, thus, downregulated CD44 expression. miR‑7 was revealed to directly bind to the TGFBR2 3'UTR through dual‑luciferase reporter assay, and Smad3, a transcription factor, through ChIP‑PCR was demonstrated to bind to the upstream region of the CD44 promoter. These results demonstrated the existence of the ALDH1A3‑miR‑7‑TGFBR2‑Smad3‑CD44 axis in MDA‑MB‑231 cells. RT‑qPCR results of 12 breast cancer surgical specimens and SK‑BR‑3, MCF‑7, and LD cell lines further confirmed the presence of the regulatory axis. In conclusion the findings from the present study demonstrated that the ALDH1A3‑miR‑7‑TGFBR2‑Smad3‑CD44 regulatory axis was highly efficient in the inhibition of CD44 expression in BCSCs, and that the regulatory expression of ALDH1A3 and miR‑7 may provide a strategy in the therapy of breast cancer.

View Figures

View References

1	Gonzalez-Angulo AM, Morales-Vasquez F and Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 608:1–22. 2007.PubMed/NCBI View Article : Google Scholar
2	Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011.PubMed/NCBI View Article : Google Scholar
3	Dou J, Li Y, Zhao F, Hu W, Wen P, Tang Q, Chu L, Wang Y, Cao M, Jiang C and Gu N: Identification of tumor stem-like cells in a mouse myeloma cell line. Cell Mol Biol (Noisy-le-grand). 55 (Suppl):OL1151–OL1160. 2009.PubMed/NCBI
4	Bravo-Egana V, Rosero S, Molano RD, Pileggi A, Ricordi C, Domínguez-Bendala J and Pastori RL: Quantitative differential expression analysis reveals miR-7 as major islet microRNA. Biochem Biophys Res Commun. 366:922–926. 2008.PubMed/NCBI View Article : Google Scholar
5	Junn E, Lee KW, Jeong BS, Chan TW, Im JY and Mouradian MM: Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci USA. 106:13052–13057. 2009.PubMed/NCBI View Article : Google Scholar
6	Li X and Carthew RW: A microRNA mediates EGF receptor signaling and promotes photoreceptor differentiation in the Drosophila eye. Cell. 123:1267–1277. 2005.PubMed/NCBI View Article : Google Scholar
7	Zhang H, Cai K, Wang J, Wang X, Cheng K, Shi F, Jiang L, Zhang Y and Dou J: miR-7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway. Stem Cells. 32:2858–2868. 2014.PubMed/NCBI View Article : Google Scholar
8	Li M, Pan M, You C, Zhao F, Wu D, Guo M, Xu H, Shi F, Zheng D and Dou J: miR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth. Breast Cancer Res. 22(26)2020.PubMed/NCBI View Article : Google Scholar
9	Pan M, Li M, You C, Zhao F, Guo M, Xu H, Li L, Wang L and Dou J: Inhibition of breast cancer growth via miR-7 suppressing ALDH1A3 activity concomitant with decreasing breast cancer stem cell subpopulation. J Cell Physiol. 235:1405–1416. 2020.PubMed/NCBI View Article : Google Scholar
10	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
11	Mon-López D and Tejero-González CM: Validity and reliability of the TargetScan ISSF Pistol & Rifle application for measuring shooting performance. Scand J Med Sci Sports. 29:1707–1712. 2019.PubMed/NCBI View Article : Google Scholar
12	Dou J, Wang Y, Yu F, Yang H, Wang J, He X, Xu W, Chen J and Hu K: Protection against Mycobacterium tuberculosis challenge in mice by DNA vaccine Ag85A-ESAT-6-IL-21 priming and BCG boosting. Int J Immunogenet. 39:183–190. 2012.PubMed/NCBI View Article : Google Scholar
13	Cibi DM, Mia MM, Guna Shekeran S, Yun LS, Sandireddy R, Gupta P, Hota M, Sun L, Ghosh S and Singh MK: Neural crest-specific deletion of Rbfox2 in mice leads to craniofacial abnormalities including cleft palate. Elife. 8(e45418)2019.PubMed/NCBI View Article : Google Scholar
14	Fornes O, Castro-Mondragon JA, Khan A, van der Lee R, Zhang X, Richmond PA, Modi BP, Correard S, Gheorghe M, Baranašić D, et al: JASPAR 2020: Update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 48 (D1):D87–D92. 2020.PubMed/NCBI View Article : Google Scholar
15	Khan A, Fornes O, Stigliani A, Gheorghe M, Castro-Mondragon JA, van der Lee R, Bessy A, Chèneby J, Kulkarni SR, Tan G, et al: JASPAR 2018: Update of the open-access database of transcription factor binding profiles and its web framework. Nucleic Acids Res. 46 (D1):D260–D266. 2018.PubMed/NCBI View Article : Google Scholar
16	Kawakami R, Mashima T, Kawata N, Kumagai K, Migita T, Sano T, Mizunuma N, Yamaguchi K and Seimiya H: ALDH1A3-mTOR axis as a therapeutic target for anticancer drug-tolerant persister cells in gastric cancer. Cancer Sci. 111:962–973. 2020.PubMed/NCBI View Article : Google Scholar
17	Yamashita D, Minata M, Ibrahim AN, Yamaguchi S, Coviello V, Bernstock JD, Harada S, Cerione RA, Tannous BA, La Motta C, et al: Identification of ALDH1A3 as a viable therapeutic target in breast cancer metastasis-initiating cells. Mol Cancer Ther. 19:1134–1147. 2020.PubMed/NCBI View Article : Google Scholar
18	Wang S, Zhou X, Liang C, Bao M, Tian Y, Zhu J, Zhang T, Yang J and Wang Z: ALDH1A3 serves as a predictor for castration resistance in prostate cancer patients. BMC Cancer. 20(387)2020.PubMed/NCBI View Article : Google Scholar
19	Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003.PubMed/NCBI View Article : Google Scholar : Erratum in: Proc Natl Acad Sci USA 100: 6890, 2003.
20	Fillmore C and Kuperwasser C: Human breast cancer stem cell markers CD44 and CD24: Enriching for cells with functional properties in mice or in man? Breast Cancer Res. 9(303)2007.PubMed/NCBI View Article : Google Scholar
21	Zhao P, Xu Y, Wei Y, Qiu Q, Chew TL, Kang Y and Cheng C: The CD44s splice isoform is a central mediator for invadopodia activity. J Cell Sci. 129:1355–1365. 2016.PubMed/NCBI View Article : Google Scholar
22	Zhang H, Brown RL, Wei Y, Zhao P, Liu S, Liu X, Deng Y, Hu X, Zhang J, Gao XD, et al: CD44 splice isoform switching determines breast cancer stem cell state. Genes Dev. 33:166–179. 2019.PubMed/NCBI View Article : Google Scholar
23	Sun C, Sun L, Jiang K, Gao DM, Kang XN, Wang C, Zhang S, Huang S, Qin X, Li Y, et al: NANOG promotes liver cancer cell invasion by inducing epithelial-mesenchymal transition through NODAL/SMAD3 signaling pathway. Int J Biochem Cell Biol. 45:1099–1108. 2013.PubMed/NCBI View Article : Google Scholar : Erratum in: Int J Biochem Cell Biol 105: 144, 2018.
24	Itatani Y, Kawada K and Sakai Y: Transforming growth factor-β signaling pathway in colorectal cancer and its tumor microenvironment. Int J Mol Sci. 20(E5822)2019.PubMed/NCBI View Article : Google Scholar
25	Vitiello GAF, Amarante MK, Banin-Hirata BK, Campos CZ, de Oliveira KB, Losi-Guembarovski R and Watanabe MAE: Transforming growth factor beta receptor II (TGFBR2) promoter region polymorphism in Brazilian breast cancer patients: Association with susceptibility, clinicopathological features, and interaction with TGFB1 haplotypes. Breast Cancer Res Treat. 178:207–219. 2019.PubMed/NCBI View Article : Google Scholar
26	Kumar R, Conklin DS and Mittal V: High-throughput selection of effective RNAi probes for gene silencing. Genome Res. 13:2333–2340. 2003.PubMed/NCBI View Article : Google Scholar
27	Zhao L and Zhang Y and Zhang Y: Long noncoding RNA CASC2 regulates hepatocellular carcinoma cell oncogenesis through miR-362-5p/Nf-κB axis. J Cell Physiol. 233:6661–6670. 2018.PubMed/NCBI View Article : Google Scholar
28	Xie X, Lu J, Kulbokas EJ, Golub TR, Mootha V, Lindblad-Toh K, Lander ES and Kellis M: Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature. 434:338–345. 2005.PubMed/NCBI View Article : Google Scholar